What is UroGen Pharma's change in accrued liabilities?

UroGen Pharma (URGN) reported change in accrued liabilities of -$3.68M in Q1 2026.

How has UroGen Pharma's change in accrued liabilities changed year-over-year?

UroGen Pharma's change in accrued liabilities decreased by 2.1% year-over-year, from -$3.6M to -$3.68M.

What does change in accrued liabilities mean?

Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.

UroGen Pharma URGN Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Merck & Co.MRK

-$460.25M+20.9%

ImmunityBio, Inc.IBRX

$3.14M+124%

CG OncologyCGON

$1.61M+92.2%

Nuvation BioNUVB

-$12.32M-37.8%

LQD

Liquidia CorporationLQDA

$14.53M+402%

Krystal Biotech, Inc.KRYS

-$6.31M-271%

Other financials

Income statement

See full

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

See full

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

See full

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

See full

Market cap$1.73B+71.7%

Enterprise value$1.81B+80.9%

P/S12.3×+1.3×

Profitability

See full

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

See full

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is UroGen Pharma's change in accrued liabilities?: UroGen Pharma (URGN) reported change in accrued liabilities of -$3.68M in Q1 2026.
How has UroGen Pharma's change in accrued liabilities changed year-over-year?: UroGen Pharma's change in accrued liabilities decreased by 2.1% year-over-year, from -$3.6M to -$3.68M.
What does change in accrued liabilities mean?: Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.